Rallybio

This morning Rallybio announced our fourth quarter and full year 2024 financial results and business updates. Read our press release: bit.ly/4hxoqvq #Rallybio #RLYB #biotech #earnings

Rallybio has dosed the first participant in the RLYB212 Ph2 clinical trial in pregnant women at higher risk for HPA-1a alloimmunization and FNAIT. Key data readouts from the sentinel participant are expected in 2Q 2025 and 3Q 2025. #RareDisease #RLYB212 #Rallybio $RLYB

#MaternalHealthAwaresnessDay we reflect on how Rh disease is nearly eradicated thanks to innovation & early detection. At Rallybio, we're working to do the same for FNAIT. Together, we can transform #maternalhealth with better testing & treatments. #RLYB116

Thanks to @ScripEleanor and @PharmaScrip for including our Founder & Chairman Martin Mackay’s thoughts on Eroom’s law & how the FDA can plan for an influx of pending drug submissions in this piece on what’s to come for biopharma in 2025! insights.citeline.com/scrip/scrip-as…

This January, we’re raising awareness for #BirthDefectsAwarenessMonth and advancing solutions for maternal and fetal health. Learn more from organizations like the @NBDPN.

🩺 RLYB116: PK/PD study launch (Q2), Cohort 1/2 data readouts (Q3, Q4) 🧑‍⚕️ REV102: IND activities (Q1), Preclinical data (2H 2025) Here’s to another year of pushing boundaries to bring transformative therapies to those who need them most. #RareDisease #2025Goals (2/2)

With 2025 underway, we’re gearing up for key milestones in our mission to advance rare disease therapies: 🤰 RLYB212: Phase 2 dosing begins (Q2), Interim data (mid-year, Q3, Q4) investors.rallybio.com/news-releases/… (1/2)

2025 is the year to advance maternal and neonatal health. Meet our team in San Francisco next week to learn about our mission to eradicate #FNAIT, a rare and potentially life-threatening disease  #JPM25 #JPM2025

As we work to improve maternal and fetal health outcomes, we're inspired by this year’s roadmap on biomarker science, clinical study design, and data analysis, fostering collaboration and innovation in maternal care. Read more here: fda.gov/consumers/abou… #WomensHealth

The FDA’s updated Women’s Health Research Roadmap advances research and safety for FDA-regulated products for women.

Read more here: businesswire.com/news/home/2024…

Our mission is to lead the charge in preventative healthcare through early screenings and education on rare maternal diseases like FNAIT. We recently initiated our Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and FNAIT.

#DidYouKnow? 4 in 5 pregnancy-related deaths in the U.S. are preventable.

It was great to see our colleagues Mark Ma and Amanda Hayward, along with many of our partners including Huiying Zhi from Versiti, at the ASH conference earlier this week to share exciting data from our RLYB212 and RLYB332 programs!

Were you able to make it to @ASH_hematology this year? If so, you may have seen some exciting new data from the Rallybio pipeline shared throughout the weekend on RLYB212 and RLYB332! Check out both posters on our site here: rallybio.com/publications-p…

Our CFO Jon Lieber proudly represented Rallybio at last night's #Fierce50 Gala, where we were an Innovation honoree! 🥂 We have much to look forward to next year and are another step closer to transforming lives. Thank you, @FiercePharma! #RareDisease fiercepharma.com/pharma/rallybio

🌴In Coral Gables today for the 7th Annual Evercore HealthCONx Conference? Don’t miss our co-founder and CEO Dr. Stephen Uden’s fireside chat Wednesday, December 4th at 12:30 p.m. ET. Listen live to today’s webcast: wsw.com/webcast/everco…

We discussed recent updates and our plans to advance RLYB116, an innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases. investors.rallybio.com/news-releases/… #RLYB116 #RareDisease

Did you tune in to our webcast on Harnessing the Power of C5 Inhibition this morning to learn the latest news about our RLYB116 program? Listen back to today’s webcast: investors.rallybio.com/events/event-d…

As we gather this Thanksgiving, we’re grateful for the innovation, resilience, and passion of those who drive forward our work every day. Thank you to our team, partners, and community for making our work possible. Wishing you and your loved ones a safe and joyful holiday season